Loading
Leads thoracic oncology at NCC East and the LC-SCRUM-Japan network that connects rare-driver lung cancer patients to trials.
Koichi Goto is Chief of the Department of Thoracic Oncology at the National Cancer Center Hospital East in Japan. He has led Japanese and global trials of RET, ROS1, MET and HER2 inhibitors in non-small-cell lung cancer, including selpercatinib and trastuzumab deruxtecan, and directs the clinical side of LC-SCRUM-Japan, one of the largest genomic screening efforts in lung cancer, which connects patients with rare drivers to trials. His publications include the DESTINY-Lung02 trial of trastuzumab deruxtecan in HER2-mutant lung cancer, a phase 2 study of crizotinib in East Asian patients with ROS1-positive disease, and the LURET trial of vandetanib in RET-rearranged lung cancer. His interests are rare oncogenic drivers and genomic screening.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial | Journal of Clinical Oncology | 2023 |
| Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2018 |
| Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial | The Lancet Respiratory Medicine | 2017 |
Shares National Cancer Center Hospital East, National Cancer Center Hospital, Trastuzumab deruxtecan.
Shares National Cancer Center Hospital, RET, Non-small-cell lung cancer.
Shares RET, MET, HER2, Non-small-cell lung cancer.
Shares ROS1, Selpercatinib, RET, Non-small-cell lung cancer.
Shares ROS1, Selpercatinib, RET, Non-small-cell lung cancer.
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, HER2.